Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of ...

As AstraZeneca kicks off the third year of its hockey-themed “Get Body Checked Against Cancer” campaign, the pharma has tapped two celebs known for their work both on and off the ice. | As AstraZeneca ...

Skyhawk Therapeutics has named Aaron Deves as chief commercial officer, securing the expertise of an executive who oversaw ...

After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis (PsA). | After ...

Eli Lilly is infusing $3 billion into its manufacturing operations in China, pledging to set up local production and supply for oral solid drugs as it works on building out capacity for its experim | ...

Veeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the ...

About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. | About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an ...

What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...

AbbVie’s CEO Robert Michael is emerging from his sophomore year at the helm with $32.5 million in 2025 compensation, marking a hefty 75% spike from his first-year pay and solidifying the rising chi | ...

In BioNTech’s search for a new CEO—following the announcement earlier Tuesday that Uğu | Leerink Partners called the departure of BioNTech CEO Uğur Şahin and his wife, and CMO Özlem Türeci, to ...

Amid the company’s efforts to resolve issues raised during an FDA inspection early last year, Novo Nordisk’s operating base in Plainsboro, New Jersey—already the recipient of a recent Form 483—has ...

After nearly nine years as GSK’s CEO, Emma Walmsley exited on a high note as her total compensation for 2025 surged nearly 50% to 15.7 million pounds sterling ($21 million). | After nearly nine years ...